AS03B-H7N9 vaccine clinical study

Ended Awarded Last action

Contract number
75A50119F33009
Awardee
Awarding agency
Obligated
$18,161,554

Award facts

Opportunity
Contract value 100% obligated
$18,161,554.28 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
Pricing
Firm Fixed Price
Place of performance
Durham, NC 27709, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00009 -$1
Other Administrative Action P00008 $0
Other Administrative Action P00007 · The purpose of this modification is to extend the period of performance of GSK?s contract #HHSO10020160004I task order 75A50119F33009; from 8/27/2019-11/30/2023… $0
Other Administrative Action P00006 · Duns number: 167380711 UEI: FRHTPHMZMX47 the purpose of this no-cost modification is to update the glaxosmithkline, LLC address to 410 blackwell ST, durham,… $0
Other Administrative Action P00005 $0
Other Administrative Action P00004 $0
Other Administrative Action P00003 · Duns number: 167380711 UEI: FRHTPHMZMX47 the purpose of this modification is to activate the invoice processing platform (IPP) for this task order in the… $0
Funding Only Action P00002 · The purpose of this modification is to update the task order clin 0013- clinical study as follows: 1) extend the task order?s POP end date from 1 july 2022 to… $614,887
Other Administrative Action P00001 $0
Original award $17,546,668

About this award

Written by GovTribe AI ·

This is a modification to an existing delivery order contract (#HHSO10020160004I, Task Order 75A50119F33009) awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to GlaxoSmithKline, LLC. The purpose of the modification is to extend the period of performance from August 28, 2019 to February 28, 2024, to a new end date of April 30, 2024. The contract is for an AS03B-H7N9 vaccine clinical study, with a total ceiling value of $18,161,554.28. The contract is a firm fixed-price delivery order with no set-aside designation. This contract is part of the Pandemic Influenza Preparedness and Response 2016-2021 indefinite delivery vehicle, which allows for the procurement of various vaccines and medical countermeasures across multiple federal agencies.

Quick answers

Who was awarded contract 75A50119F33009?

75A50119F33009 was awarded to Glaxosmithkline, LLC by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on August 28, 2019.

How much is contract 75A50119F33009 worth?

The government has obligated $18,161,554 on 75A50119F33009.

Is contract 75A50119F33009 an order under another contract?

Yes. 75A50119F33009 is a delivery order under HHSO100201600004I, an indefinite delivery contract, on Pandemic Influenza Preparedness and Response 2016-2021.

Was contract 75A50119F33009 competed?

The extent of competition for 75A50119F33009 was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login